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Radiation-Induced Myonecrosis Presenting as a
Subcutaneous Mass After Combined Modality
Therapy for Non-small Cell Lung Cancer
Vamsidhar Velcheti, MD,* Eve Gilstrap, RN,* Jeffrey Bradley, MD,†‡ and Ramaswamy Govindan, MD*‡
(J Thorac Oncol. 2007;2: 875–876)
A 60-year-old African-American man with a long historyof tobacco smoking presented with a lung nodule de-
tected incidentally on a chest radiograph in November 2004.
Computerized tomography (CT) confirmed the presence of a
5  3-cm mass in the left upper lobe with mediastinal lymph
node involvement (T2 N2 M0). CT-guided biopsy findings
were consistent with squamous cell carcinoma. He received
four cycles of paclitaxel (175 mg/m2) and carboplatin (area
under the curve 5) along with thoracic radiation to the left
upper lobe mass and mediastinum on a q 3-week cycle. The
radiation dose prescription was 7000 cGy to the planning
target volume delivered in 200-cGy daily fractions using
6-mV beams. The dose to the isocenter within the target
volume was 7350 cGy (Figure 1). The dose was prescribed
using lung density corrections. A four-field beam arrange-
ment was used consisting of anterior-posterior, posterior-
anterior, left posterior oblique, and right anterior oblique
beams. The patient tolerated the concurrent chemoradiation
well. He did experience esophagitis (grade 2) toward the end
of the radiation treatment, which was treated symptomati-
cally. Overall, he had a partial response based on the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) crite-
ria. Six months later, the patient developed pain and swelling
in his upper back. On physical examination, he had mild
tenderness over the left paraspinal region. There was a vague
nodular swelling in the upper mid back in the field of
radiation. A CT scan of the chest revealed an ill-defined low
attenuation lesion within the left trapezius muscle lying
medial to the left scapula at the level of the fifth and sixth ribs
without invasion of the underlying ribs or the adjacent scap-
ula grossly (Figure 2). This area of abnormality corresponds
to the 5000-cGy radiation isodose line in Figure 1. An
ultrasound of the lesion revealed thickening with contour
abnormality in the musculature corresponding to the area of
the abnormality seen on the previous CT examination. This
region was hyperechoic compared with normal muscle. This
region was adequately visualized by sonography, and a bi-
opsy was performed. This biopsy demonstrated findings of
skeletal muscle with marked necrosis and fibrosis but no
evidence of malignancy. A fluorodeoxyglucose positron
emission tomography scan prior to the biopsy did not reveal
any uptake in this lesion. A repeat CT-guided biopsy of the
soft tissue mass revealed only benign-appearing epithelial
cells with scattered elongated nucleoli, probably representing
fibroblasts. There were no features diagnostic for malignancy.
A follow-up evaluation 4 months later showed sponta-
neous resolution of the mass (Figure 3). Given the lack of
uptake on the emission tomography scan, three negative
biopsies, and spontaneous resolution, it was deemed consis-
tent with radiation myonecrosis. The patient has subsequently
been followed more than 15 months without any evidence of
recurrence.
DISCUSSION
Concurrent chemotherapy and thoracic radiation is con-
sidered the standard of treatment for patients with unresect-
able locally advanced non-small cell lung cancer (NSCLC).
Concurrent chemoradiation is associated with acute and de-
layed complications. Radiation therapy for lung cancer often
involves a radiation dose through a limited number of portals.
However, administration of the dose through fewer portals
entails increased skin and subcutaneous doses. Figure 1
shows two areas of high dose to the subcutaneous tissue and
skin (both anteriorly and posteriorly).
Skeletal muscles are relatively radio-resistant, and lo-
calized damage to the muscular tissue is uncommon at ther-
apeutic doses. Radiation-induced myonecrosis has been re-
ported only rarely in the literature.1–4 Radiation-induced
myonecrosis results from vascular insufficiency from prolif-
eration of collagen resulting in ischemia within 10 months of
exposure. Use of concurrent chemotherapy along with radi-
ation increases the risk of both acute and delayed radiation-
related side effects.5
Paclitaxel is a chemotherapeutic agent commonly used
in multimodality treatment of patients with NSCLC in com-
bination with thoracic radiation because of its ability to
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radiosensitize the tumors. Paclitaxel’s anti cancer effect is
mediated by its ability to alter the stability of tubulin polymer
subunits and thereby promote apoptosis in tumor cells. Pac-
litaxel and docetaxel-induced radiation recall cutaneous re-
actions have been reported in literature.6 Chemotherapy reg-
imens containing gemcitabine have occasionally been
reported to induce radiation myositis,7,8 but there have been
no reports suggesting the affect of paclitaxel on radiation-
induced damage of the skeletal muscles. Our patient was
treated with four cycles of paclitaxel (175 mg/m2), along with
concurrent radiation therapy. It is possible that the myone-
crosis in our patient was secondary to inflammatory radiation-
induced changes potentiated by paclitaxel.
The development of an intramuscular nodule in a pa-
tient with locally advanced NSCLC naturally would arouse
the suspicion of recurrent disease. Radiation-induced myone-
crosis should be considered in the differential diagnosis if the
nodule is in the field of radiation.
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FIGURE 2. A computed tomographic scan of the chest re-
vealed an ill-defined low-attenuation lesion within the left
trapezius muscle lying medial to the left scapula at the level
of the fifth and sixth ribs without invasion of the underlying
ribs or the adjacent scapula grossly.
FIGURE 1. The dose to the isocenter within the target vol-
ume was 7350 cGy.
FIGURE 3. A computed tomographic-guided biopsy of the
soft tissue mass revealed only benign-appearing epithelial
cells with scattered elongated nucleoli, probably represent-
ing fibroblasts. There were no features diagnostic for malig-
nancy. A follow-up evaluation 4 months later showed spon-
taneous resolution of the mass.
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